Cargando…
Effect of cholecalciferol on serum hepcidin and parameters of anaemia and CKD-MBD among haemodialysis patients: a randomized clinical trial
In this multicentre double-blind randomized clinical trial, we investigated the effects of oral cholecalciferol supplementation on serum hepcidin and parameters related to anaemia and CKD-MBD among haemodialysis patients. Participants were assigned in a 2:2:1:1 ratio to either (1) thrice-weekly 3,00...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7512011/ https://www.ncbi.nlm.nih.gov/pubmed/32968158 http://dx.doi.org/10.1038/s41598-020-72385-w |
_version_ | 1783586070820028416 |
---|---|
author | Obi, Yoshitsugu Yamaguchi, Satoshi Hamano, Takayuki Sakaguchi, Yusuke Shimomura, Akihiro Namba-Hamano, Tomoko Mikami, Satoshi Nishi, Osamu Tanaka, Motoko Kamoto, Akihito Obi, Yasue Tomosugi, Naohisa Tsubakihara, Yoshiharu Isaka, Yoshitaka |
author_facet | Obi, Yoshitsugu Yamaguchi, Satoshi Hamano, Takayuki Sakaguchi, Yusuke Shimomura, Akihiro Namba-Hamano, Tomoko Mikami, Satoshi Nishi, Osamu Tanaka, Motoko Kamoto, Akihito Obi, Yasue Tomosugi, Naohisa Tsubakihara, Yoshiharu Isaka, Yoshitaka |
author_sort | Obi, Yoshitsugu |
collection | PubMed |
description | In this multicentre double-blind randomized clinical trial, we investigated the effects of oral cholecalciferol supplementation on serum hepcidin and parameters related to anaemia and CKD-MBD among haemodialysis patients. Participants were assigned in a 2:2:1:1 ratio to either (1) thrice-weekly 3,000-IU cholecalciferol, (2) once-monthly cholecalciferol (equivalent to 9,000 IU/week), (3) thrice-weekly placebo, or (4) once-monthly placebo. We also examined the effect modifications by selected single nucleotide polymorphisms in vitamin D-related genes. Out of 96 participants, 94 were available at Month 3, and 88 completed the 6-month study. After adjustment for baseline values, serum hepcidin levels were higher at Day 3 in the combined cholecalciferol (vs. placebo) group, but were lower at Month 6 with increased erythropoietin resistance. Cholecalciferol increased serum 1,25(OH)(2)D levels, resulting in a greater proportion of patients who reduced the dose of active vitamin D at Month 6 (31% vs. 10% in the placebo group). Cholecalciferol also suppressed intact PTH only among patients with severe vitamin D deficiency. In conclusion, cholecalciferol supplementation increases serum hepcidin-25 levels in the short term and may increase erythropoietin resistance in the long term among haemodialysis patients. Both thrice-weekly and once-monthly supplementation effectively increases serum 1,25(OH)(2)D levels, and hence, reduces active vitamin D drugs. Clinical Trial Registry: This study was registered at ClinicalTrials.gov and University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) as NCT02214563 (registration date: 12/08/2014) and UMIN000011786 (registration date: 15/08/2014), respectively (please refer to the links below). ClinicalTrials.gov: https://clinicaltrials.gov/ct2/show/record/NCT02214563. UMIN-CTR: https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&type=summary&recptno=R000017152&language=E. |
format | Online Article Text |
id | pubmed-7512011 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-75120112020-09-29 Effect of cholecalciferol on serum hepcidin and parameters of anaemia and CKD-MBD among haemodialysis patients: a randomized clinical trial Obi, Yoshitsugu Yamaguchi, Satoshi Hamano, Takayuki Sakaguchi, Yusuke Shimomura, Akihiro Namba-Hamano, Tomoko Mikami, Satoshi Nishi, Osamu Tanaka, Motoko Kamoto, Akihito Obi, Yasue Tomosugi, Naohisa Tsubakihara, Yoshiharu Isaka, Yoshitaka Sci Rep Article In this multicentre double-blind randomized clinical trial, we investigated the effects of oral cholecalciferol supplementation on serum hepcidin and parameters related to anaemia and CKD-MBD among haemodialysis patients. Participants were assigned in a 2:2:1:1 ratio to either (1) thrice-weekly 3,000-IU cholecalciferol, (2) once-monthly cholecalciferol (equivalent to 9,000 IU/week), (3) thrice-weekly placebo, or (4) once-monthly placebo. We also examined the effect modifications by selected single nucleotide polymorphisms in vitamin D-related genes. Out of 96 participants, 94 were available at Month 3, and 88 completed the 6-month study. After adjustment for baseline values, serum hepcidin levels were higher at Day 3 in the combined cholecalciferol (vs. placebo) group, but were lower at Month 6 with increased erythropoietin resistance. Cholecalciferol increased serum 1,25(OH)(2)D levels, resulting in a greater proportion of patients who reduced the dose of active vitamin D at Month 6 (31% vs. 10% in the placebo group). Cholecalciferol also suppressed intact PTH only among patients with severe vitamin D deficiency. In conclusion, cholecalciferol supplementation increases serum hepcidin-25 levels in the short term and may increase erythropoietin resistance in the long term among haemodialysis patients. Both thrice-weekly and once-monthly supplementation effectively increases serum 1,25(OH)(2)D levels, and hence, reduces active vitamin D drugs. Clinical Trial Registry: This study was registered at ClinicalTrials.gov and University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) as NCT02214563 (registration date: 12/08/2014) and UMIN000011786 (registration date: 15/08/2014), respectively (please refer to the links below). ClinicalTrials.gov: https://clinicaltrials.gov/ct2/show/record/NCT02214563. UMIN-CTR: https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&type=summary&recptno=R000017152&language=E. Nature Publishing Group UK 2020-09-23 /pmc/articles/PMC7512011/ /pubmed/32968158 http://dx.doi.org/10.1038/s41598-020-72385-w Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Obi, Yoshitsugu Yamaguchi, Satoshi Hamano, Takayuki Sakaguchi, Yusuke Shimomura, Akihiro Namba-Hamano, Tomoko Mikami, Satoshi Nishi, Osamu Tanaka, Motoko Kamoto, Akihito Obi, Yasue Tomosugi, Naohisa Tsubakihara, Yoshiharu Isaka, Yoshitaka Effect of cholecalciferol on serum hepcidin and parameters of anaemia and CKD-MBD among haemodialysis patients: a randomized clinical trial |
title | Effect of cholecalciferol on serum hepcidin and parameters of anaemia and CKD-MBD among haemodialysis patients: a randomized clinical trial |
title_full | Effect of cholecalciferol on serum hepcidin and parameters of anaemia and CKD-MBD among haemodialysis patients: a randomized clinical trial |
title_fullStr | Effect of cholecalciferol on serum hepcidin and parameters of anaemia and CKD-MBD among haemodialysis patients: a randomized clinical trial |
title_full_unstemmed | Effect of cholecalciferol on serum hepcidin and parameters of anaemia and CKD-MBD among haemodialysis patients: a randomized clinical trial |
title_short | Effect of cholecalciferol on serum hepcidin and parameters of anaemia and CKD-MBD among haemodialysis patients: a randomized clinical trial |
title_sort | effect of cholecalciferol on serum hepcidin and parameters of anaemia and ckd-mbd among haemodialysis patients: a randomized clinical trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7512011/ https://www.ncbi.nlm.nih.gov/pubmed/32968158 http://dx.doi.org/10.1038/s41598-020-72385-w |
work_keys_str_mv | AT obiyoshitsugu effectofcholecalciferolonserumhepcidinandparametersofanaemiaandckdmbdamonghaemodialysispatientsarandomizedclinicaltrial AT yamaguchisatoshi effectofcholecalciferolonserumhepcidinandparametersofanaemiaandckdmbdamonghaemodialysispatientsarandomizedclinicaltrial AT hamanotakayuki effectofcholecalciferolonserumhepcidinandparametersofanaemiaandckdmbdamonghaemodialysispatientsarandomizedclinicaltrial AT sakaguchiyusuke effectofcholecalciferolonserumhepcidinandparametersofanaemiaandckdmbdamonghaemodialysispatientsarandomizedclinicaltrial AT shimomuraakihiro effectofcholecalciferolonserumhepcidinandparametersofanaemiaandckdmbdamonghaemodialysispatientsarandomizedclinicaltrial AT nambahamanotomoko effectofcholecalciferolonserumhepcidinandparametersofanaemiaandckdmbdamonghaemodialysispatientsarandomizedclinicaltrial AT mikamisatoshi effectofcholecalciferolonserumhepcidinandparametersofanaemiaandckdmbdamonghaemodialysispatientsarandomizedclinicaltrial AT nishiosamu effectofcholecalciferolonserumhepcidinandparametersofanaemiaandckdmbdamonghaemodialysispatientsarandomizedclinicaltrial AT tanakamotoko effectofcholecalciferolonserumhepcidinandparametersofanaemiaandckdmbdamonghaemodialysispatientsarandomizedclinicaltrial AT kamotoakihito effectofcholecalciferolonserumhepcidinandparametersofanaemiaandckdmbdamonghaemodialysispatientsarandomizedclinicaltrial AT obiyasue effectofcholecalciferolonserumhepcidinandparametersofanaemiaandckdmbdamonghaemodialysispatientsarandomizedclinicaltrial AT tomosuginaohisa effectofcholecalciferolonserumhepcidinandparametersofanaemiaandckdmbdamonghaemodialysispatientsarandomizedclinicaltrial AT tsubakiharayoshiharu effectofcholecalciferolonserumhepcidinandparametersofanaemiaandckdmbdamonghaemodialysispatientsarandomizedclinicaltrial AT isakayoshitaka effectofcholecalciferolonserumhepcidinandparametersofanaemiaandckdmbdamonghaemodialysispatientsarandomizedclinicaltrial |